Jacobs Levy Equity Management Inc. Sells 44,153 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Jacobs Levy Equity Management Inc. cut its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL) by 52.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 39,521 shares of the company’s stock after selling 44,153 shares during the period. Jacobs Levy Equity Management Inc. owned approximately 0.06% of Replimune Group worth $433,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. LMR Partners LLP raised its position in shares of Replimune Group by 145.8% during the third quarter. LMR Partners LLP now owns 82,479 shares of the company’s stock worth $904,000 after purchasing an additional 48,920 shares during the period. Millennium Management LLC increased its stake in Replimune Group by 575.1% during the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock worth $28,062,000 after purchasing an additional 2,656,173 shares in the last quarter. Cubist Systematic Strategies LLC raised its holdings in Replimune Group by 282.2% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company’s stock worth $650,000 after buying an additional 53,313 shares during the period. Acadian Asset Management LLC lifted its stake in Replimune Group by 63.2% in the second quarter. Acadian Asset Management LLC now owns 185,516 shares of the company’s stock valued at $1,668,000 after buying an additional 71,867 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Replimune Group in the third quarter valued at approximately $251,000. 92.53% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on REPL. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Replimune Group in a research report on Friday, November 22nd. Roth Capital upgraded Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Roth Mkm began coverage on Replimune Group in a report on Tuesday, August 27th. They set a “buy” rating and a $17.00 price objective for the company. Jefferies Financial Group boosted their target price on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, December 4th. Finally, BMO Capital Markets raised their price target on shares of Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a research note on Friday, November 22nd. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $17.29.

Replimune Group Trading Down 3.4 %

Shares of Replimune Group stock opened at $12.64 on Tuesday. The stock has a market cap of $864.83 million, a P/E ratio of -4.14 and a beta of 1.26. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. Replimune Group, Inc. has a 12-month low of $4.92 and a 12-month high of $17.00. The business’s 50 day moving average is $12.14 and its 200-day moving average is $10.32.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.07. Equities research analysts predict that Replimune Group, Inc. will post -2.91 earnings per share for the current fiscal year.

Insider Activity at Replimune Group

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction on Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the transaction, the insider now directly owns 109,885 shares of the company’s stock, valued at $1,184,560.30. The trade was a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 8.80% of the stock is currently owned by company insiders.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.